Compare HUN & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HUN | DRTS |
|---|---|---|
| Founded | 1970 | 2015 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2004 | 2021 |
| Metric | HUN | DRTS |
|---|---|---|
| Price | $9.58 | $13.00 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 15 | 5 |
| Target Price | $10.29 | ★ $17.80 |
| AVG Volume (30 Days) | ★ 2.8M | 431.9K |
| Earning Date | 11-02-2026 | 11-19-2026 |
| Dividend Yield | ★ 3.90% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,683,000,000.00 | N/A |
| Revenue This Year | $8.36 | N/A |
| Revenue Next Year | $2.01 | $1,235.59 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.30 | $3.43 |
| 52 Week High | $16.09 | $15.79 |
| Indicator | HUN | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 64.70 | 42.71 |
| Support Level | $9.42 | $11.24 |
| Resistance Level | $9.99 | $13.95 |
| Average True Range (ATR) | 0.37 | 0.63 |
| MACD | 0.15 | 0.01 |
| Stochastic Oscillator | 98.12 | 45.44 |
Huntsman Corp is a USA-based manufacturer of differentiated organic chemical products. The product portfolio of the company comprises Methyl diphenyl diisocyanate (MDI), Amines, Maleic anhydride, and Epoxy-based polymer formulations. The company's products are used in adhesives, aerospace, automotive, and construction products, and others. Its operating segments are Polyurethanes, Performance Products, and Advanced Materials. The company derives the majority of its revenue from the Polyurethanes segment, which includes MDI, polyols, TPU (thermoplastic polyurethane), and other polyurethane-related products. Its geographical segments are the United States & Canada, Europe, Asia-Pacific, and the Rest of the world.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.